Back

Effects of residual risk–targeted therapies on coronary plaque regression: a network meta-analysis of 40 studies

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Improved targeting of risk factors and residual risk Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Mattia Galli

Sapienza University of Rome, Rome (Italy)

6 More presentations in this session

Presentation thumbnail
Vericiguat improves MRI-assessed coronary endothelial function in patients with metabolic syndrome or type 2 diabetes mellitus
Doctor T. Harb (Baltimore, US)
Abstract
Presentation thumbnail
Association of dysglycaemic indices with coronary anatomical complexity in non-diabetic patients presenting with acute coronary syndrome
Doctor M. Merry (Ismailia, EG)
Abstract
Presentation thumbnail
Lipid management in patients with coronary artery disease at risk of a first major atherosclerotic cardiovascular event: findings from the VESALIUS-REAL global study
Professor G. De Ferrari (Turin, IT)
Abstract
Presentation thumbnail
The hypothyroidism paradox: treated thyroid status as a long-term catalyst for LDL-C target attainment post-percutaneous coronary intervention
Miss T. Simonneau (Cordoba, ES)
Abstract
Presentation thumbnail
Impact of a personalized, fire-to-target lipid-lowering strategy in patients with acute coronary syndrome
Doctor J. Herrera (Cordoba, ES)
Abstract

Access the full session

Session thumbnail
Improved targeting of risk factors and residual risk

The Event

Event poster

ESC Congress 2026

29 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparing coronary artery plaque regression in patients treated with ezetimibe or PCSK9 inhibitors following acute coronary syndrome: a systematic review and meta-analysis
29 August 2025
thumbnail
Congress Presentation
Efficacy of additional medical therapies in patients with heart failure, a reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis
29 June 2021
thumbnail
Congress Session
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
29 August 2022
thumbnail
Congress Presentation
Modelling the long-term clinical outcomes of AI-enabled CCTA plaque quantification on preventive cardiovascular management
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources